stocks logo

SHC

Sotera Health Co
$
12.300
+0.19(1.569%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
12.460
Open
12.190
VWAP
12.23
Vol
1.29M
Mkt Cap
3.49B
Low
12.040
Amount
15.74M
EV/EBITDA(TTM)
11.82
Total Shares
283.07M
EV
5.50B
EV/OCF(TTM)
20.39
P/S(TTM)
3.17
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
313.62M
+8.07%
0.232
+10.56%
298.27M
+4.48%
0.203
+19.17%
275.94M
-0.24%
0.173
-9.15%
Estimates Revision
The market is revising Upward the revenue expectations for Sotera Health Company (SHC) for FY2025, with the revenue forecasts being adjusted by 0.67% over the past three months. During the same period, the stock price has changed by 9.24%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.67%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.35%
In Past 3 Month
Stock Price
Go Up
up Image
+9.24%
In Past 3 Month
4 Analyst Rating
up Image
17.89% Upside
Wall Street analysts forecast SHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SHC is 14.50 USD with a low forecast of 13.00 USD and a high forecast of 17.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
up Image
17.89% Upside
Current: 12.300
sliders
Low
13.00
Averages
14.50
High
17.00
Barclays
Overweight
maintain
$15 -> $13
2025-06-24
Reason
Barclays lowered the firm's price target on Sotera Health to $13 from $15 and keeps an Overweight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.
Piper Sandler
Jason Bednar
Hold
Maintains
$15 → $13
2025-04-23
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping, with Becton Dickinson (BDX) and Sotera Health (SHC) looking best positioned to respond favorably to upcoming reports when considering current sentiment/positioning.
Barclays
Luke Sergott
Buy
Maintains
$16 → $12
2025-04-10
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Sotera Health to $12 from $16 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Barclays
Luke Sergott
Buy
Maintains
$17 → $16
2025-02-28
Reason
Barclays
Luke Sergott
Buy
Maintains
$18 → $17
2025-02-18
Reason
RBC Capital
Sean Dodge
Buy
Reiterates
$17
2024-11-21
Reason

Valuation Metrics

The current forward P/E ratio for Sotera Health Co (SHC.O) is 16.04, compared to its 5-year average forward P/E of 20.30. For a more detailed relative valuation and DCF analysis to assess Sotera Health Co 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
20.30
Current PE
16.04
Overvalued PE
26.54
Undervalued PE
14.07

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
12.90
Current EV/EBITDA
9.44
Overvalued EV/EBITDA
16.85
Undervalued EV/EBITDA
8.94

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
4.75
Current PS
2.97
Overvalued PS
6.61
Undervalued PS
2.89

Financials

Annual
Quarterly
FY2025Q1
YoY :
+2.56%
254.52M
Total Revenue
FY2025Q1
YoY :
+7.28%
57.04M
Operating Profit
FY2025Q1
YoY :
-309.71%
-13.26M
Net Income after Tax
FY2025Q1
YoY :
-350.00%
-0.05
EPS - Diluted
FY2025Q1
YoY :
-241.33%
35.60M
Free Cash Flow
FY2025Q1
YoY :
+5.15%
47.19
Gross Profit Margin - %
FY2025Q1
YoY :
-127.35%
9.57
FCF Margin - %
FY2025Q1
YoY :
-304.31%
-5.21
Net Margin - %
FY2025Q1
YoY :
-100.00%
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
601.2M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 140.83% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
6.6K
Volume
1
6-9
Months
76.4K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
7.0M
Volume
Months
6-9
2
2.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

SHC News & Events

Events Timeline

2025-05-01 (ET)
2025-05-01
07:41:49
Sotera Health reaffirms FY25 adjusted EPS view 70c-76c, consensus 74c
select
2025-05-01
07:41:04
Sotera Health reports Q1 adjusted EPS 14c, consensus 12c
select
2025-03-04 (ET)
2025-03-04
07:22:56
Sotera's Nelson Labs launches rapid sterility testing to expedite results
select
Sign Up For More Events

News

6.0
06-24Benzinga
Barclays Maintains Overweight on Sotera Health, Lowers Price Target to $13
2.0
06-18NASDAQ.COM
Strength Seen in PACS Group, Inc. (PACS): Can Its 21.8% Jump Turn into More Strength?
9.5
05-05Benzinga
Sotera Health 'Is Uniquely Insulated From Potential Tariff Policy,' Goldman Sachs Says
Sign Up For More News

FAQ

arrow icon

What is Sotera Health Co (SHC) stock price today?

The current price of SHC is 12.3 USD — it has increased 1.57 % in the last trading day.

arrow icon

What is Sotera Health Co (SHC)'s business?

arrow icon

What is the price predicton of SHC Stock?

arrow icon

What is Sotera Health Co (SHC)'s revenue for the last quarter?

arrow icon

What is Sotera Health Co (SHC)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Sotera Health Co (SHC)'s fundamentals?

arrow icon

How many employees does Sotera Health Co (SHC). have?

arrow icon

What is Sotera Health Co (SHC) market cap?